{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,9]],"date-time":"2026-07-09T20:24:34Z","timestamp":1783628674984,"version":"3.55.0"},"reference-count":28,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100016808","name":"Natural Science Foundation of Xiamen Municipality","doi-asserted-by":"publisher","award":["3502Z202573051"],"award-info":[{"award-number":["3502Z202573051"]}],"id":[{"id":"10.13039\/100016808","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Fitoterapia"],"published-print":{"date-parts":[[2026,4]]},"DOI":"10.1016\/j.fitote.2026.107201","type":"journal-article","created":{"date-parts":[[2026,3,22]],"date-time":"2026-03-22T22:58:31Z","timestamp":1774220311000},"page":"107201","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"special_numbering":"C","title":["Natural product PROTACylation: Development of Maslinic acid-based JAK2 degraders for cancer therapy"],"prefix":"10.1016","volume":"190","author":[{"given":"Ziqing","family":"Zhang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Weiming","family":"Lu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tongtong","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peixi","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wenpei","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daxin","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jieqing","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.fitote.2026.107201_bb0005","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1186\/s13045-024-01640-8","article-title":"Global burden of cancer and associated risk factors in 204 countries and territories, 1980\u20132021: a systematic analysis for the GBD 2021","volume":"17","author":"Wu","year":"2024","journal-title":"J. Hematol. Oncol."},{"issue":"4","key":"10.1016\/j.fitote.2026.107201_bb0010","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1038\/nrclinonc.2018.8","article-title":"Targeting the IL-6\/JAK\/STAT3 signalling axis in cancer","volume":"15","author":"Johnson","year":"2018","journal-title":"Nat. Rev. Clin. Oncol."},{"issue":"1","key":"10.1016\/j.fitote.2026.107201_bb0015","doi-asserted-by":"crossref","first-page":"21","DOI":"10.4049\/jimmunol.1401867","article-title":"Mechanisms of jak\/STAT signaling in immunity and disease","volume":"194","author":"Villarino","year":"2015","journal-title":"J. Immunol."},{"issue":"11","key":"10.1016\/j.fitote.2026.107201_bb0020","doi-asserted-by":"crossref","first-page":"3008","DOI":"10.1158\/1078-0432.CCR-11-3145","article-title":"Ruxolitinib: the first FDA approved therapy for the treatment of myelofibrosis","volume":"18","author":"Mascarenhas","year":"2012","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.fitote.2026.107201_bb0025","doi-asserted-by":"crossref","first-page":"82","DOI":"10.12688\/f1000research.13167.1","article-title":"JAK inhibitors for the treatment of myeloproliferative neoplasms and other disorders","volume":"7","author":"Vainchenker","year":"2018","journal-title":"F1000Research"},{"key":"10.1016\/j.fitote.2026.107201_bb0030","doi-asserted-by":"crossref","DOI":"10.1016\/j.jcis.2025.138203","article-title":"Engineering an advanced multicomponent pentacyclic triterpenoid nanoplatform for synergistic co-delivery of cyclin-dependent kinase 4\/6 inhibitors to enhance cancer chemoimmunotherapy","volume":"699","author":"Zhou","year":"2025","journal-title":"J. Colloid Interface Sci."},{"issue":"8","key":"10.1016\/j.fitote.2026.107201_bb0035","doi-asserted-by":"crossref","first-page":"11538","DOI":"10.3390\/molecules190811538","article-title":"Maslinic acid, a natural phytoalexin-type triterpene from olives \u2014 a promising nutraceutical?","volume":"19","author":"Lozano-Mena","year":"2014","journal-title":"Molecules"},{"issue":"1","key":"10.1016\/j.fitote.2026.107201_bb0040","doi-asserted-by":"crossref","DOI":"10.1186\/1471-2407-11-154","article-title":"The natural triterpene maslinic acid induces apoptosis in HT29 colon cancer cells by a JNK-p53-dependent mechanism","volume":"11","author":"Reyes-Zurita","year":"2011","journal-title":"BMC Cancer"},{"issue":"2","key":"10.1016\/j.fitote.2026.107201_bb0045","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1038\/nrd.2016.211","article-title":"Induced protein degradation: an emerging drug discovery paradigm","volume":"16","author":"Lai","year":"2017","journal-title":"Nat. Rev. Drug Discov."},{"issue":"2","key":"10.1016\/j.fitote.2026.107201_bb0050","doi-asserted-by":"crossref","first-page":"444","DOI":"10.1021\/acs.jmedchem.7b01272","article-title":"Protac-induced protein degradation in drug discovery: breaking the rules or just making new ones?","volume":"61","author":"Churcher","year":"2018","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.fitote.2026.107201_bb0055","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1016\/j.cbpa.2019.02.022","article-title":"Targeted protein degradation: elements of PROTAC design","volume":"50","author":"Paiva","year":"2019","journal-title":"Curr. Opin. Chem. Biol."},{"issue":"5","key":"10.1016\/j.fitote.2026.107201_bb0060","doi-asserted-by":"crossref","first-page":"498","DOI":"10.1016\/j.ccell.2019.10.002","article-title":"A potent and selective small-molecule degrader of STAT3 achieves complete tumor regression in vivo","volume":"36","author":"Bai","year":"2019","journal-title":"Cancer Cell"},{"issue":"54","key":"10.1016\/j.fitote.2026.107201_bb0065","doi-asserted-by":"crossref","first-page":"7577","DOI":"10.1039\/C7CC03879H","article-title":"Chemically induced degradation of CDK9 by a proteolysis targeting chimera (PROTAC)","volume":"53","author":"Robb","year":"2017","journal-title":"Chem. Commun."},{"issue":"6","key":"10.1016\/j.fitote.2026.107201_bb0070","doi-asserted-by":"crossref","first-page":"4875","DOI":"10.3892\/ol.2017.6073","article-title":"Maslinic acid suppresses the growth of human gastric cells by inducing apoptosis via inhibition of the interleukin-6 mediated Janus kinase\/signal transducer and activator of transcription 3 signaling pathway","volume":"13","author":"Wang","year":"2017","journal-title":"Oncol. Lett."},{"key":"10.1016\/j.fitote.2026.107201_bb0075","doi-asserted-by":"crossref","DOI":"10.1016\/j.bioorg.2021.104901","article-title":"Design and linkage optimization of ursane-thalidomide-based PROTACs and identification of their targeted-degradation properties to MDM2 protein","volume":"111","author":"Qi","year":"2021","journal-title":"Bioorg. Chem."},{"key":"10.1016\/j.fitote.2026.107201_bb0080","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2021.113850","article-title":"Design, synthesis and biological evaluation of tyrosinase-targeting PROTACs","volume":"226","author":"Fu","year":"2021","journal-title":"Eur. J. Med. Chem."},{"issue":"8","key":"10.1016\/j.fitote.2026.107201_bb0085","doi-asserted-by":"crossref","first-page":"611","DOI":"10.1038\/nchembio.1858","article-title":"Catalytic in vivo protein knockdown by small-molecule PROTACs","volume":"11","author":"Bondeson","year":"2015","journal-title":"Nat. Chem. Biol."},{"issue":"2","key":"10.1016\/j.fitote.2026.107201_bb0090","doi-asserted-by":"crossref","first-page":"807","DOI":"10.1002\/anie.201507634","article-title":"Modular PROTAC Design for the Degradation of oncogenic BCR-ABL","volume":"55","author":"Lai","year":"2016","journal-title":"Angew. Chem. Int. Ed."},{"issue":"1","key":"10.1016\/j.fitote.2026.107201_bb0095","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1016\/j.chembiol.2019.12.006","article-title":"Exploring targeted degradation strategy for oncogenic KRASG12C","volume":"27","author":"Zeng","year":"2020","journal-title":"Cell Chem. Biol."},{"issue":"26","key":"10.1016\/j.fitote.2026.107201_bb0100","doi-asserted-by":"crossref","first-page":"7124","DOI":"10.1073\/pnas.1521738113","article-title":"PROTAC-induced BET protein degradation as a therapy for castration-resistant prostate cancer","volume":"113","author":"Raina","year":"2016","journal-title":"Proc. Natl. Acad. Sci."},{"issue":"11","key":"10.1016\/j.fitote.2026.107201_bb0105","doi-asserted-by":"crossref","first-page":"798","DOI":"10.1038\/nrc2734","article-title":"STATs in cancer inflammation and immunity: a leading role for STAT3","volume":"9","author":"Yu","year":"2009","journal-title":"Nat. Rev. Cancer"},{"issue":"5","key":"10.1016\/j.fitote.2026.107201_bb0110","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1007\/s40265-017-0701-9","article-title":"JAK\u2013STAT Signaling as a target for inflammatory and autoimmune diseases: current and future prospects","volume":"77","author":"Banerjee","year":"2017","journal-title":"Drugs"},{"issue":"7414","key":"10.1016\/j.fitote.2026.107201_bb0115","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1038\/nature11303","article-title":"Heterodimeric JAK\u2013STAT activation as a mechanism of persistence to JAK2 inhibitor therapy","volume":"489","author":"Koppikar","year":"2012","journal-title":"Nature"},{"issue":"12","key":"10.1016\/j.fitote.2026.107201_bb0120","doi-asserted-by":"crossref","DOI":"10.1101\/cshperspect.a006080","article-title":"Cell death Signaling","volume":"7","author":"Green","year":"2015","journal-title":"Cold Spring Harb. Perspect. Biol."},{"issue":"3","key":"10.1016\/j.fitote.2026.107201_bb0125","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1038\/ncb0311-184","article-title":"Integrating the mechanisms of apoptosis induced by endoplasmic reticulum stress","volume":"13","author":"Tabas","year":"2011","journal-title":"Nat. Cell Biol."},{"key":"10.1016\/j.fitote.2026.107201_bb0130","doi-asserted-by":"crossref","unstructured":"Zhang, P., et al., Advanced PROTAC and quantitative proteomics strategy reveals Bax Inhibitor-1 as a critical target of Icaritin in Burkitt lymphoma. Int. J. Mol. Sci., 2024. 25(23): p. 12944.","DOI":"10.3390\/ijms252312944"},{"issue":"3","key":"10.1016\/j.fitote.2026.107201_bb0135","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1021\/acs.jnatprod.5b01055","article-title":"Natural products as sources of new drugs from 1981 to 2014","volume":"79","author":"Newman","year":"2016","journal-title":"J. Nat. Prod."},{"key":"10.1016\/j.fitote.2026.107201_bb0140","doi-asserted-by":"crossref","unstructured":"Gao, S.P., et al., Mutations in the EGFR kinase domain mediate STAT3 activation via IL-6 production in human lung adenocarcinomas. J. Clin. Investig., 2007. 117(12): p. 3846\u20133856, J. Clin. Invest..","DOI":"10.1172\/JCI31871"}],"container-title":["Fitoterapia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0367326X26001206?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0367326X26001206?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,4,13]],"date-time":"2026-04-13T22:59:23Z","timestamp":1776121163000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0367326X26001206"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4]]},"references-count":28,"alternative-id":["S0367326X26001206"],"URL":"https:\/\/doi.org\/10.1016\/j.fitote.2026.107201","relation":{},"ISSN":["0367-326X"],"issn-type":[{"value":"0367-326X","type":"print"}],"subject":[],"published":{"date-parts":[[2026,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Natural product PROTACylation: Development of Maslinic acid-based JAK2 degraders for cancer therapy","name":"articletitle","label":"Article Title"},{"value":"Fitoterapia","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.fitote.2026.107201","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"107201"}}